头颈部肿瘤在MR直线加速器上的在线自适应放疗:引入一种新型改良的Adapt-to-Shape方法
在Elekta Unity MR直线加速器上,两例头颈部肿瘤患者接受根治剂量放疗,比较新型ATS-Lite策略与三种ATP变体(ATP-AS、ATP-OW、ATP-OS)。共分析53个分次,ATS-Lite通过99.9%的强制剂量约束,而ATP-AS和ATP-OW各失败7.6%,ATS-Lite分次中位时间分别为40分9秒和32分14秒。作者认为ATS-Lite可在患者可耐受的时间框架内满足临床剂量约束,应被考虑用于MR直线加速器上头颈部肿瘤的治疗。
要点
- ATS-Lite策略通过99.9%的强制剂量约束,ATP-AS和ATP-OW各失败7.6%。
- 54 Gy计划靶区的D95%和D98%是ATP最常失败的剂量约束目标。
- ATS-Lite分次中位时间为40分9秒和32分14秒,与ATP工作流程相当。
核心结论
- 早期数据显示,新型ATS-Lite策略产生的计划满足了99.9%的临床剂量约束,时间框架患者可耐受且与ATP工作流程相当。
- ATS-Lite弥合了ATP与完整ATS之间的差距,将在本机构内进一步使用和开发,并且是MR直线加速器上头颈部肿瘤治疗应考虑的工作流程。
研究设计与样本
- 两例头颈部肿瘤患者在Elekta Unity MR直线加速器上接受根治剂量放疗。
- 每个分次在线生成并执行ATS-Lite计划,同时离线为每种ATP变体生成额外计划。
- 对全部四种计划评估20个靶区和危及器官的临床目标以判断每个分次计划的临床可接受性。
- 共分析53个分次。
主要发现
- ATS-Lite通过99.9%的强制剂量约束。
- ATP-AS和ATP-OW各失败7.6%的强制剂量约束。
- 54 Gy计划靶区的D95%和D98%是ATP最常失败的剂量约束目标。
- 患者1的ATS-Lite分次中位时间为40分9秒(范围28分16秒至47分20秒)。
- 患者2的ATS-Lite分次中位时间为32分14秒(范围25分33秒至44分27秒)。
临床怎么用
- 作者认为ATS-Lite是MR直线加速器上头颈部肿瘤治疗应考虑的工作流程。
- ATS-Lite将在本机构内进一步使用和开发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Elekta Unity MR-Linac (MRL) has enabled adaptive radiotherapy (ART) for patients with head and neck cancers (HNC). Adapt-To-Shape-Lite (ATS-Lite) is a novel Adapt-to-Shape strategy that provides ART without requiring daily clinician presence to perform online target and organ at risk (OAR) delineation. In this study we compared the performance of our clinically-delivered ATS-Lite strategy against three Adapt-To-Position (ATP) variants: Adapt Segments (ATP-AS), Optimise Weights (ATP-OW), and Optimise Shapes (ATP-OS). METHODS: Two patients with HNC received radical-dose radiotherapy on the MRL. For each fraction, an ATS-Lite plan was generated online and delivered and additional plans were generated offline for each ATP variant. To assess the clinical acceptability of a plan for every fraction, twenty clinical goals for targets and OARs were assessed for all four plans. RESULTS: 53 fractions were analysed. ATS-Lite passed 99.9% of mandatory dose constraints. ATP-AS and ATP-OW each failed 7.6% of mandatory dose constraints. The Planning Target Volumes for 54 Gy (D95% and D98%) were the most frequently failing dose constraint targets for ATP. ATS-Lite median fraction times for Patient 1 and 2 were 40 mins 9 s (range 28 mins 16 s - 47 mins 20 s) and 32 mins 14 s (range 25 mins 33 s - 44 mins 27 s), respectively. CONCLUSIONS: Our early data show that the novel ATS-Lite strategy produced plans that fulfilled 99.9% of clinical dose constraints in a time frame that is tolerable for patients and comparable to ATP workflows. Therefore, ATS-Lite, which bridges the gap between ATP and full ATS, will be further utilised and developed within our institute and it is a workflow that should be considered for treating patients with HNC on the MRL.
引用
- Gupta A, Dunlop A, Mitchell A, et al. Online adaptive radiotherapy for head and neck cancers on the MR linear Accelerator: Introducing a novel modified Adapt-to-Shape approach. Clin Transl Radiat Oncol. 2021. PMID: 34849412. doi:10.1016/j.ctro.2021.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。